Unitaid

Lenacapavir is a long-acting HIV prevention option that requires just two injections a year.

It complements existing prevention approaches, including daily oral medication (PrEP), which helps reduce the risk of HIV infection. However, daily prevention is not always easy to maintain. People may face barriers such as stigma, access to clinics, or difficulty taking a daily pill consistently.

A 2025 partnership between Dr. Reddy's Laboratories Ltd., Unitaid the Clinton Health Access Initiative, and Wits RHI is helping translate innovation into access by enabling a pathway to affordable generic lenacapavir at around US$40 per person per year across 120 low- and middle-income countries.

The focus is on making lenacapavir affordable, scalable, and accessible so it can reach more people and support continued progress in reducing new HIV infections.

Find out more below

Margaret Happy lost her two sisters in the 1990s, when HIV treatment was not available.

Today, she works in Uganda to help prevent advanced HIV disease through timely diagnosis and care.

At Unitaid, we are working to strengthen access to CD4 testing alongside viral load testing, ensuring people can be identified and treated in time.

But in some settings, access is declining—putting timely diagnosis at risk.

Read more about why CD4 testing still matters and what’s being done to protect access.

Link below.